Rapidly Design Multiparametrically Optimized Small Molecules with Novel Chemistry Against Hard Targets, Enhance Preclinical Target Product Profiles & Expedite Timelines from Concept to IND
Cutting-edge AI/ML-driven breakthroughs, including Monte Rosa Therapeutics’ progress in molecular glue degraders, Insilico Medicine’s recent deal with Eli Lilly, the launch of Eli Lilly's TuneLab, coupled with ongoing partnerships between Merck and Variational AI, and Pfizer and XtalPi, are fueling accelerated small molecule innovation. Biopharma are actively pursuing, and investing in, AI/ML approaches that integrate computational and medicinal chemistry insights to rearchitect the small molecule discovery funnel.
The inaugural AI Convergence: Small Molecule Discovery Summit arrived at this pivotal juncture to immerse you in the applied learnings needed to catalyze the next wave of AI/ML-powered small molecule development. The 2026 summit delved into AI/ML applications that elucidated undruggable target protein folding, supercharged structure- and ligand-based design, leveraged AI/ML-enabled virtual screening to tap into unexplored chemical space, used generative molecular design for molecular glues, covalent inhibitors and degraders, optimized ADME-T, and addressed data input and federated learning platform opportunities.
The 2026 summit, united industry leaders such as Insilico Medicine, PsiThera, OpenADMET, Sanofi, Novo Nordisk, as well as newcomers including Eli Lilly’s TuneLab, Expedition Medicines and Montai Therapeutics. The Summit explored AI/ML methods, use cases and the convergence of state-of-the-art AI/ML tools, alongside existing approaches, to ignite future AI/ML-enabled small molecule discovery.
The 2026 Expert Speaker Faculty:
2026 Attending Companies Included: